Therapy Areas: Cardiovascular
Basilea Grants Cardiome Exclusive License to Distribute Zevtera/Mabelio (ceftobiprole) in Europe and Israel
13 September 2017 - - Vancouver, Canada-based cardiac disease therapeutics developer Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera/Mabelio, the company said.
Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. Cardiome will provide Basilea with an upfront payment and additional milestone payments based upon achievement of certain commercial and regulatory milestones.
As a result of the agreement, Cardiome will be responsible for the registration, promotion and commercialization of Zevtera/Mabelio in the covered countries. Cardiome plans to commercialize Zevtera/Mabelio in every European country where it currently has a direct sales force, with the potential for further distribution and expansion.
Ceftobiprole (ceftobiprole medocaril sodium) is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. 
Ceftobiprole is currently approved for sale in 13 European countries and several non-European countries for the treatment of adult patients with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia.
Cardiome Pharma is a specialty pharmaceutical company that engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases.